Extended Data Fig. 2: RFS according to prespecified subgroups. | Nature Medicine

Extended Data Fig. 2: RFS according to prespecified subgroups.

From: Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial

Extended Data Fig. 2

Shown is a forest plot of hazard ratios for disease recurrence or death among prespecified subgroups of patients in the nivolumab plus relatlimab group and nivolumab group. The hazard ratios were not stratified according to the stratification factors. The horizontal lines indicate 95% confidence intervals with the hazard ratio represented by the center dot. AJCC-8, American Joint Committee on Cancer; Cancer Staging Manual, Eighth Edition; ECOG PS, Eastern Cooperative Oncology Group performance status; LAG-3, lymphocyte activation gene 3; LDH, lactate dehydrogenase; NIVO, nivolumab; RELA, relatlimab.

Back to article page